# A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

> **NCT06514794** · PHASE2 · RECRUITING · sponsor: **Wugen, Inc.** · enrollment: 125 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **BIOLOGICAL:** WU-CART-007

## Key facts

- **NCT ID:** NCT06514794
- **Lead sponsor:** Wugen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514794, "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06514794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*